On Thursday, Shares of AbbVie Inc. (NYSE:ABBV), gained 1.03% to $65.97.
Adding an experimental drug co-developed by Bristol-Myers Squibb Co. and AbbVie Inc. to an older treatment for a type of blood cancer delayed disease progression by an average of 4½ months in patients in a new clinical trial, researchers said on Wednesday, according to WSJ.
In the study, researchers tested whether adding elotuzumab to a widely used combination of drugs would improve outcomes in patients whose multiple myeloma progressed despite past treatment. About half of the 650 patients received elotuzumab together with the drugs Revlimid and dexamethasone, while the other half received only the combination.
About 26,850 new cases of multiple myeloma are predictable to be diagnosed in the U.S. this year, and 11,240 Americans are predictable to die from it, according to the American Cancer Society. The cancer causes malignancies in plasma cells, which build up in bone marrow and displace healthy blood cells.
Patients who received elotuzumab lived a median time of 19.4 months until their disease progressed or until they died, contrast with 14.9 months in patients who received just the older combination.
About 26,850 new cases of multiple myeloma are predictable to be diagnosed in the U.S. this year, and 11,240 Americans are predictable to die from it, according to the American Cancer Society. The cancer causes malignancies in plasma cells, which build up in bone marrow and displace healthy blood cells, WSJ reports.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Shares of The Dow Chemical Company (NYSE:DOW), inclined 1.01% to $51.24, during its last trading session.
Stockholders of The Dow Chemical Company, elected Ajay Banga, Jacqueline K. Barton, James A. Bell, Richard Davis, Jeff M. Fettig, Mark Loughridge, Andrew N. Liveris, Raymond J. Milchovich, Robert S. (Steve) Miller, Paul Polman, Dennis H. Reilley, James M. Ringler and Ruth G. Shaw to the Company’s Board of Directors for one-year terms during the Company’s 118th Annual Meeting.
Stockholders also ratified the appointment of Deloitte & Touche LLP as the Company’s independent auditor for 2015.
In other business, preliminary voting results indicate that stockholders have approved an advisory vote on executive compensation and a stockholder-sponsored proposal regarding limiting accelerated executive pay has been defeated.
The Dow Chemical Company manufactures and supplies products that are used primarily as raw materials in the manufacture of customer products and services worldwide. It operates through Agricultural Sciences, Consumer Solutions, Infrastructure Solutions, Performance Materials & Chemicals, and Performance Plastics segments.
At the end of Thursday’s trade, Shares of Baker Hughes Incorporated (NYSE:BHI), lost -1.50% to $65.50.
Baker Hughes Incorporated, Chairman and Chief Executive Officer Martin S. Craighead declared that the Baker Hughes Board of Directors declared the regular quarterly cash dividend of $0.17 per share of common stock payable June 24, 2015 to holders of record on June 3, 2015.
Baker Hughes Incorporated supplies oilfield services, products, technology, and systems to the oil and natural gas industry worldwide. The company offers drilling and evaluation products and services, which comprise drill bits for performance drilling, hole enlargement, and coring; conventional and rotary steerable systems used to drill wells; measurement-while-drilling and logging-while-drilling systems to perform reservoir navigation services; drilling optimization services; tools for coil tubing drilling and wellbore re-entry systems; coring drilling systems; surface logging; emulsion and water-based drilling fluids systems; reservoir drill-in fluids; and fluids environmental services.
Finally, Pepsico, Inc. (NYSE:PEP), ended its last trade with 1.65% gain, and closed at $98.
PepsiCo’s Frito-Lay North America division is encouraging families to take a walk on the wild side this summer. Through a partnership with the Association of Zoos & Aquariums (AZA), Frito-Lay is encouraging families to explore the magic of wildlife while assisting to protect endangered species. The partnership, which is being promoted through Frito-Lay’s variety pack line of snacks, kicks off on National Endangered Species Day (May 15) with an effort to support AZA SAFE: Saving Animals From Extinction. Starting May 15, Frito-Lay will rally families to support AZA SAFE with a commitment to match every dollar donated to support endangered species conservation through www.FritoLayZooFun.com, up to a maximum of $100,000, through June 15, 2015.
PepsiCo, Inc. operates as a food and beverage company worldwide. Its Frito-Lay North America segment offers Lay’s potato chips, Doritos tortilla chips, Cheetos cheese-flavored snacks, Tostitos tortilla chips, branded dips, Ruffles potato chips, Fritos corn chips, and Santitas tortilla chips.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
